Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention

With the global rise in diabetes prevalence, the burden of diabetic kidney disease (DKD) is projected to escalate substantially, contributing to increased morbidity, mortality, and healthcare costs. This narrative review aims to synthesize contemporary evidence on guideline-directed medical therapy (GDMT) for DKD, with a specific focus on primary prevention, secondary prevention, and real-world implementation of evidence-based pharmacologic and non-pharmacologic strategies to mitigate renal and cardiovascular risk. A comprehensive literature review (published 2012-2025) was conducted, integrating international clinical guidelines, landmark randomized controlled trials, meta-analyses, and implementation studies addressing the prevention and management of DKD. Recent advances in GDMT have reshaped the therapeutic landscape of DKD. Lifestyle interventions - including dietary optimization, regular physical activity, and smoking cessation - demonstrate meaningful renoprotective and cardiometabolic benefits. Pharmacologic therapies, such as renin-angiotensin system (RAS) blockade, sodium-glucose co-transporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have shown robust efficacy in reducing albuminuria, slowing estimated glomerular filtration rate (eGFR) decline, and lowering cardiovascular events. Landmark trials report relative risk reductions of approximately 30-40% in kidney disease progression with SGLT2 inhibitors and 18-23% reductions in renal and cardiovascular composite outcomes with finerenone and GLP-1 RAs. Despite strong guideline endorsement, real-world uptake of GDMT remains suboptimal, particularly in low-resource healthcare settings. Early detection through routine eGFR and urine albumin-to-creatinine ratio screening, combined with timely initiation and sustained implementation of GDMT, offers the most effective strategy to alter the natural history of DKD. Integrating lifestyle modification with optimized pharmacotherapy is essential to reducing long-term renal and cardiovascular complications.